Get notified when PLSE files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Immediate Dilution of $23.53 Per Share (new) — New investors pay $25.46 for shares with a net tangible book value of about $1.93, resulting in substantial dilution.
- Outstanding Options and Warrants With Exercise Prices Below the Offering Price (new) — 13,086,288 options with a weighted-average exercise price of $11.87 and 202,812 warrants at $11.00 could further dilute investors if exercised.
Pulse Biosciences launches at-the-market offering of up to $60M, with shares priced at market
Filed February 19, 2026 · ~1 min read
Key Changes
-
high
Pulse Biosciences is offering up to $59,976,196 of common stock via an at-the-market program, with shares sold at prevailing market prices.
The Offering verify on EDGAR → -
high
The company will receive all proceeds from the primary shares; no secondary shares are being sold by insiders.
The Offering verify on EDGAR → -
medium
Net proceeds are earmarked for general corporate purposes, including clinical evaluations of its nPulse Cardiac Catheter and Clamp, commercialization of the Pulse Vybrance system, and regulatory efforts for benign thyroid nodules.
Use of Proceeds verify on EDGAR →
2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (SAR 10-Q) is open in full — no account needed.
Partner
Trade PLSE commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Sep 2, 2026 · How we verify